PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
PTC(PTC) Prnewswire·2024-11-26 21:30- Study failed to meet primary and secondary efficacy endpoints -WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis. While there was modest numerical benefit recorded on the primary endpoint and correlation of favorable clinical effect with lowering of plasma neurofilament light chain (NfL), ...